21:38 on July 22, 2019, Immuron Ltd (IMRN.us) shares changed, and the share price rose 5.57% rapidly. As of press time, the stock was trading at US $3.22 per share, with a turnover of 3113 shares, a turnover rate of 0.08% and an amplitude of 1.31%.

The latest 2018-12-31 data show that the stock achieved operating income of $708526.00, net profit of-$1.15 million, earnings per share of-$0.34, gross profit of $538951.22, and price-to-earnings ratio of-5.68 times.

In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.

The biotech industry in which Immuron Ltd shares are located rose 0.16% as a whole. Among its related stocks, Onconova Therapeutics Inc, Kazia Therapeutics Ltd and Azurrx Biopharma Inc rose significantly, while Xenetic Biosciences Inc, Intec Pharma Ltd and Neuralstem Inc were more active, with turnover rates of 116.19%, 15.40% and 11.07% respectively, and Xenetic Biosciences Inc, Azurrx Biopharma Inc and Neuralstem Inc with large amplitudes of 41.24%, 21.90% and 14.24%, respectively.

About Immuron Ltd: Immuron is a biopharmaceutical company that develops polyclonal antibodies for the treatment and prevention of diseases. Its products include Travelan, IMM-124E for the treatment of NASH, and IMM-529 for Clostridium labile infection.

(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )